Tristel shares have slipped in 2024, and the pullback is prompting a fresh question about whether the current price lines up with the cash the business is expected to produce. For a stock built on disinfectant and infection prevention products, the key issue now is how its share price compares with the value suggested by its future cash flows.
The issue now is whether Tristel's current £3.85 share price is adequately backed by the intrinsic value indicated by its projected cash flows under a Discounted Cash Flow (DCF) approach.
If you want more than a single-stock view and prefer to compare Tristel with other businesses through the same cash flow lens, a focused screener built around 14 high quality undervalued stocks can be a useful next step.
The Discounted Cash Flow (DCF) model here is built around the cash Tristel is expected to generate for shareholders over time. Latest twelve month free cash flow sits at about £9.1 million, with the projection used in the model rising to around £12.5 million by the 2029 financial year, so the framework assumes a growing stream of cash rather than a shrinking one.
Those forecasts blend analyst estimates for the next few years with more mechanical growth assumptions further out, then discount everything back to today in £ terms. When that is weighed against the current £3.85 share price, the DCF projections put Tristel's estimated intrinsic value substantially above the current share price. This means the market price implies a more cautious view of the future cash generation than this model does. Find out what Tristel could be worth using our Discounted Cash Flow (DCF) estimate.
Simply Wall St Narratives for Tristel pick up where the DCF puzzle leaves off and explain what combination of future growth, profitability and earnings power would need to occur for the share price to sit meaningfully above or below where it trades today. Each narrative ties a specific number to a clear view of how Tristel's revenue trajectory, margins and potential risks might evolve. This gives you something concrete to revisit as fresh information comes through.
One of the top narratives on Tristel: 18% undervalued
This Narrative is the analyst consensus Narrative on Simply Wall St, which compiles analysts' consensus price target and revenue and earnings forecasts, not one person's view.
"The main thing that has to go right is that Tristel converts its guideline endorsements, digital platforms and new product launches into sustained adoption in target hospitals…"
Discover why this Narrative puts Tristel at 18% undervalued.
Price and cash flow only tell part of the story, because the people steering Tristel and the way they are rewarded can heavily shape how that story unfolds over time. See who runs Tristel and how they are paid.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com